A prospective cohort identified concomitant medication patterns alongside weight change, without isolating a benzodiazepine mechanism.
The analysis included 392 olanzapine-treated patients and modeled weight and metabolic changes over follow-up. Treatment duration and coprescribing of several medicine classes, including benzodiazepines, were associated with greater weight gain in the reported analyses.
The paper’s central question concerned olanzapine dose and metabolic outcomes. The benzodiazepine finding was a concomitant-treatment association, not a randomized comparison of adding or withholding a specific sedative.
Clinical severity, sleep disturbance, activity, diet, and other treatment differences can influence both coprescribing and weight. An adjusted association does not establish which factor caused the change. The category also does not identify the same effect for every benzodiazepine.
For review, reconstruct baseline weight, follow-up interval, actual medication use, and other metabolic risk factors. The study supports treating co-medication as relevant context, while it cannot assign an individual’s weight gain to a benzodiazepine or establish a drug-specific metabolic mechanism.
Original analysis of the supplied journal article, identified as PMC9305461.